Jaypirca is approved for CLL/SLL patients previously treated with covalent BTK inhibitors, offering a new treatment option. The BRUIN-CLL-321 trial showed Jaypirca improved progression-free survival ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) ...

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...

Findings showed pirtobrutinib was noninferior to ibrutinib in both the pre-treated and intent-to-treat populations for the endpoint of ORR. Topline data were announced from a head-to-head phase 3 ...

The data also show how the economic burden of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is increasing. New data suggest patients who receive a diagnosis of chronic lymphocytic ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...

Tuesday 6 January 2026 1 SLL = 0.00004768 USD 0.00004769 0.00004769 SLL USD rate for 06/01/2026 Monday 5 January 2026 1 SLL = 0.00004768 USD 0.00004769 0.00004769 SLL USD rate for 05/01/2026 Sunday 4 ...

Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor This expanded ...

Conditional survival is the probability that a patient with a given disease will survive an additional number of years based on the fact that he or she has already survived a specific number of years.

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...

Understanding the diagnosis and treatment options empowered the patient, fostering a sense of control and preparedness. Maintaining a positive mental attitude and aligning with supportive healthcare ...

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib ...